CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• CXC chemokine receptor 4 (CXCR4) is a G protein-coupled receptor involved in numerous diseases.
• Aberrant CXCR4 signaling and overexpression are linked to cancer progression.
• CXCR4 activation by CXCL12 triggers various intracellular pathways crucial for malignancy.

Purpose of the Study:

• To develop and validate a panel of assays for screening CXCR4 modulators.
• To identify pathway-selective antagonists of CXCR4 signaling.
• To explore biased antagonists for targeted therapeutic intervention.

Main Methods:

• Development of assays measuring Gα(i)-mediated cyclic adenosine monophosphate modulation, β-arrestin recruitment, and receptor internalization.
• Screening of a 30,000-small-molecule library against CXCR4.
• Profiling of hit compounds using the developed assay panel.

Main Results:

• Identification of compounds with selective antagonist activity on Gα(i)-dependent pathways.
• Discovery of antagonists affecting both β-arrestin and Gα(i) pathways, with some inducing receptor internalization.
• Characterization of compounds acting as antagonists across all tested pathways.

Conclusions:

• Pathway-selective CXCR4 antagonists (biased antagonists) were identified.
• These biased antagonists modulate CXCR4 function and downstream signaling differentially.
• Targeted modulation of CXCR4 signaling pathways presents a potential therapeutic strategy for diseases driven by aberrant CXCR4 activity.